BCLC Outperforms HKLC Staging of Hepatocellular Carcinoma in Multiethnic Asians – Real-World Perspective ESPS Manuscript NO: 32584.

Slides:

Advertisements

Similar presentations

Intermediate stage HCC management

Advertisements

FT in prognostic of HBV FibroTest: predictive value in HBV.

Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.

TACE for HCC in a regional centre: 5 year audit and assessment of baseline predictors of outcome Iain DS Morrison, #R Kasthuri, EH Forrest, S Barclay,

Dr. Mohammed Omar Khalifa

Results of Definitive Radiotherapy in Anal Canal Carcinoma

Living donor liver transplantation: Eastern experiences

The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy Kidney Blood Press Res 2016;41: DOI: /

Volume 105, Issue 3, Pages (March 1994)

Masatoshi Kudo Clinical Gastroenterology and Hepatology

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer.

Compassionate People World Class Care

Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.

SIRveNIB: Randomized Phase III Trial of Selective Internal Radiation Therapy vs Sorafenib in Locally Advanced HCC CCO Independent Conference Highlights*

Oncol Res Treat 2016;39: DOI: /

Radioembolization for hepatocellular carcinoma

P2X 7 Receptor and APOE Polymorphisms and Survival from Heart Failure: A Prospective Study in Frail Patients in a Geriatric Unit Giuseppe Pasqualetti;Marta.

A New Model to Estimate Survival for Hepatocellular Carcinoma Patients

Marcelo Calil Instituto Brasileiro de Controle do Câncer

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy Jae.

Supplementary Table 1. Dissociation cases of EI and Fibrosis Case 1 2

Volume 146, Issue 7, Pages e3 (June 2014)

Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience M.-C.

MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma Liver Cancer 2017;6: DOI: /

Journal Club Leona von Köckritz

Focus on hepatocellular carcinoma

HEPATOCELLULAR CARCINOMA (HCC) at

Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.

Volume 64, Issue 3, Pages (March 2016)

Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.

Marcus-Alexander Wörns, Peter Robert Galle Journal of Hepatology

Volume 152, Issue 8, Pages (June 2017)

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Clinical outcome after SVR: ANRS CO22 HEPATHER

Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum Markers Hidenori Toyoda, Takashi Kumada, Yukio Osaki, Hiroko.

Volume 146, Issue 7, Pages e3 (June 2014)

VIETNAM MILITARY MEDICAL UNIVERSITY

4155 primary hepatocellular carcinoma with known diagnosis month/year

Radioembolization for hepatocellular carcinoma

Alan J. Wigg, Rosemary McCormick, Rachel Wundke, Richard J. Woodman

Epidemiology & First option of treatment

Hashem B. El-Serag, Thomas P

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

Enrollment and Outcomes

Volume 136, Issue 5, Pages (May 2009)

Volume 148, Issue 7, Pages (June 2015)

Table 6.1.1: Stock and Flow, *based on year of death Year

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis.

Volume 66, Issue 3, Pages (March 2017)

CHAPTER 2 PRIMARY GLOMERULONEPHRITIS

Liver Transplantation for Hepatocellular Carcinoma

Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy Jae.

Figure 3. Survival rates according to renal dysfunction

Hashem B. El-serag, Thomas Tran, James E. Everhart Gastroenterology

Masatoshi Kudo Clinical Gastroenterology and Hepatology

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma Jin-de Chen, Chun-jen Liu, Po-huang Lee, Pei-jer.

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

Kaplan-Meier survival curve for all catheterisations.

Multidisciplinary team approach to hepatocellular carcinoma management in a liver transplant center from Romania Cerban R.1, Iacob S.1, Croitoru A.1, Popescu.

Table 6.1.1: Stock and Flow, Year

Figure Prevalence of coronary artery disease by year or

Friedrich Foerster, Peter Robert Galle JHEP Reports

Presentation transcript:

BCLC Outperforms HKLC Staging of Hepatocellular Carcinoma in Multiethnic Asians – Real-World Perspective ESPS Manuscript NO: 32584

Figure 1a. Barcelona Clinic Liver Cancer (BCLC) staging system2

Figure 1b. Hong Kong Liver Cancer (HKLC) staging system5

Figure 2a. Kaplan-Meier survival curve according to BCLC staging system Cumulative Survival 5 10 15 20 25 Survival Time (Years)

Figure 2b. Kaplan-Meier survival curve according to HKLC staging system Cumulative Survival 5 10 15 20 25 30 Survival Time (Years)

Figure 3. Patients receiving curative treatment after assignment to curative treatment groups by BCLC and HKLC staging systems Percentage BCLC Curative Stages 0 and A HKLC Curative Stages I, II and Va BCLC Stage 0 BCLC Stage A HKLC Stage I HKLC Stage II HKLC Stage Va *Figures in percentage

Age (in years) / Percentage Figure 4. Comparison of characteristics of patients assigned by HKLC staging system to curative treatment who did and did not receive recommended treatment Age (in years) / Percentage

Figure 5. Median survival of patients assigned to curative treatment by BCLC and HKLC staging systems Cumulative Survival 5 10 15 20 25 30 Survival Time (Years)

Figure 6. Median survival of patients who received the assigned curative treatment according to the BCLC and HKLC staging systems Cumulative Survival 5 10 15 20 25 30 Survival Time (Years)

Table 1. Baseline characteristics Variable All Patients (n = 1,270) Age in years, median (range) 63 (13 to 94) Male, n (%) 1046 (82.4) Ethnicity Chinese 1135 (89.4) Malay 90 (7.1) Indian 36 (2.8) Others 9 (0.7) Aetiology Hepatitis B 953 (75.0) Hepatitis C 91 (7.2) Hepatitis B and C co-infection 48 (3.8) 178 (14.0) Child-Pugh class A:B:C 641 (50.5): 452 (35.6): 177 (13.9)